Data from EMC - Curated by Toby Galbraith - Last updated 17 March 2017

Licensing authority

EMA (European Medicines Agency)

Indication(s)

Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Acute and Advanced Heart Failure

What are the most effective treatments for acute heart failure? Can you define advanced heart failure? Discover here...

Visit Acute and Advanced Heart Failure

Bedwetting

Essential screening, diagnosis and best strategies to manage bedwetting

Visit Bedwetting

More information

Category Value
Agency product number EMEA/H/C/001160
Orphan designation No
Date First Approved 04-11-2009
Type POM
Marketing authorisation holder Novartis Europharm Ltd.

Related Content